# Systemic anti-cancer therapy for advanced non-small-cell lung cancer

## Squamous non-small cell lung cancer, NTRK fusion positive, PD‑L1 below 50%

Initial recommended treatment options are:

* platinum doublet chemotherapy or
* the [NICE technology appraisal guidance on pembrolizumab with carboplatin and paclitaxel](https://www.nice.org.uk/guidance/ta770).

For people who have disease progression after initial treatment with platinum doublet chemotherapy, recommended treatment options are:

* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428) (if PD-L1 above 1%) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta520) (any PD-L1 0% to 100%) or
* the [NICE technology appraisal guidance on nivolumab](https://www.nice.org.uk/guidance/ta655) (any PD-L1 0% to 100%) or
* docetaxel.

For people who have had initial treatment with platinum doublet chemotherapy and who have disease progression after treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428), [atezolizumab](https://www.nice.org.uk/guidance/ta520) or [nivolumab](https://www.nice.org.uk/guidance/ta655), the next recommended treatment option is docetaxel.

For people who have had treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428), [atezolizumab](https://www.nice.org.uk/guidance/ta520) or [nivolumab](https://www.nice.org.uk/guidance/ta655), and who have disease progression after follow-up treatment with docetaxel, recommended treatment options (available through the Cancer Drugs Fund) are:

* the [NICE technology appraisal guidance on entrectinib](https://www.nice.org.uk/guidance/ta644) or
* the [NICE technology appraisal guidance on larotrectinib](https://www.nice.org.uk/guidance/ta630).

For people who have had initial treatment with platinum doublet chemotherapy and who have disease progression after treatment with docetaxel, recommended treatment options are:

* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428) (if PD-L1 above 1%) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta520) (any PD-L1 0% to 100%) or
* the [NICE technology appraisal guidance on nivolumab](https://www.nice.org.uk/guidance/ta655) (any PD-L1 0% to 100%).

For people who have had treatment with docetaxel and who have disease progression after follow-up treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428), [atezolizumab](https://www.nice.org.uk/guidance/ta520) or [nivolumab](https://www.nice.org.uk/guidance/ta655), recommended treatment options (available through the Cancer Drugs Fund) are:

* the [NICE technology appraisal guidance on entrectinib](https://www.nice.org.uk/guidance/ta644) or
* the [NICE technology appraisal guidance on larotrectinib](https://www.nice.org.uk/guidance/ta630).

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab with carboplatin and paclitaxel](https://www.nice.org.uk/guidance/ta770), the next recommended treatment option is docetaxel.

For people who have had initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab with carboplatin and paclitaxel](https://www.nice.org.uk/guidance/ta770) and who have disease progression after follow-up treatment with docetaxel, recommended treatment options (available through the Cancer Drugs Fund) are:

* the [NICE technology appraisal guidance on entrectinib](https://www.nice.org.uk/guidance/ta644) or
* the [NICE technology appraisal guidance on larotrectinib](https://www.nice.org.uk/guidance/ta630).